MET and neoplasm: Moreover, single-cell analysis of circulating tumor cells has unveiled compelling insights into the effectiveness of HGF/c-MET inhibitors, such as rilotumumab (formerly AMG102) and compound A (a c-MET small molecule inhibitor), in curtailing cancer progression post-surgery.